Scarica l'app Stockscreener
0.8108
1.92%
0.0153
Dopo l'orario di chiusura:
.79
-0.0208
-2.57%
Precedente Chiudi:
$0.7955
Aprire:
$0.8077
Volume 24 ore:
418.33K
Relative Volume:
0.56
Capitalizzazione di mercato:
$93.59M
Reddito:
$3.17M
Utile/perdita netta:
$-36.23M
Rapporto P/E:
-1.9834
EPS:
-0.4088
Flusso di cassa netto:
$-17.11M
1 W Prestazione:
+6.80%
1M Prestazione:
-5.50%
6M Prestazione:
-3.45%
1 anno Prestazione:
+60.55%
Intervallo 1D:
$0.7982
$0.8297
Intervallo di 1 settimana:
$0.74
$0.8517
Portata 52W:
$0.4453
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Nome
Rani Therapeutics Holdings Inc
Settore
Industria
Telefono
(408) 457-3700
Indirizzo
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.8108 | 87.63M | 3.17M | -36.23M | -17.11M | -0.4088 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | Lake Street | Buy |
| 2024-08-02 | Iniziato | Oppenheimer | Outperform |
| 2024-06-14 | Iniziato | Maxim Group | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-07-27 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Rani Therapeutics Holdings Inc Borsa (RANI) Ultime notizie
Rani Therapeutics CEO Imran Talat Withholds Shares for Tax on RSU Settlement - kalkinemedia.com
Form 4 Rani Therapeutics Holdings Inc Class A For: 29 September - Investing.com Nigeria
Tax withholding left Rani Therapeutics (RANI) CEO Imran Talat holding 461,808 shares. - Stock Titan
Stock-award tax withholding leaves Rani Therapeutics (RANI) CTO with 9,071 shares. - Stock Titan
Rani Therapeutics (RANI) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
RANI Stock Price, Quote & Chart - ChartMill
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Definium Therapeutics (DFTX) and enGene Holdings (ENGN) - The Globe and Mail
Rani Therapeutics Holdings (RANI) Trades at $0.82, Holding a Narrow Sub-$1 RangeMerger Arbitrage - careplusvn.com
Rani Therapeutics at H.C. Wainwright: oral biologics gain traction By Investing.com - Investing.com UK
RANI: RaniPill's strong clinical data and major partnerships drive growth, with manufacturing and cash runway secured - TradingView
Rani Therapeutics (RANI) Institutional Ownership 2026 $RANI - MarketBeat
Rani Therapeutics Holdings, Inc. (RANI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rani Therapeutics will appear in New York on Sept. 10 and 14 - Stock Titan
Rani Therapeutics Holdings Stock Price Forecast. Should You Buy RANI? - StockInvest.us
Rani Therapeutics Holdings Inc (RANI) Peer Comparison – Compare with Others - Value Research
RANI Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pre-Revenue StageProfit Inflection Point - dars.gov.et
Rani Therapeutics Holdings Inc (RANI) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Rani (RANI) Earnings Report: EPS Beats Its Estimate in Latest Trading; Trading Response: The Stock Gains 3.41% on the DayGuidance Accuracy Score - vinanet.vn
Rani (RANI) Trading: Finishes 3.41% Up at $0.88 in the Latest Session; Technical View: the Supplied Trading Band Runs From $0.84 to $0.92 in the Available RecordTWAP Entry - vinanet.vn
HC Wainwright Reaffirms "Buy" Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
H.C. Wainwright reiterates Rani Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Rani Therapeutics stock rating at buy - Investing.com
We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely - webull.com
Chardan Capital Maintains Rani Therapeutics(RANI.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tues - Benzinga
Chardan Capital Initiates Coverage on Rani Therapeutics (NASDAQ:RANI) - MarketBeat
RANI Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Jump 9.5%Dividend Earnings Report - careplusvn.com
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline - MarketBeat
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Rani Therapeutics (RANI) Edges Lower to $0.80 as Stock Tests Crucial Support ZonePercent Below MA - vinanet.vn
RA Capital details 11,530,414 Rani Therapeutics (RANI) shares under 9.99% cap - Stock Titan
Rani Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates - Investing.com Canada
8-K: Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Updatemoomoo - Moomoo
Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Rani Therapeutics Q2 Results: EPS beats estimate, sales up 85% - scanx.trade
Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue - Stock Titan
Rani Therapeutics reports Q2 2026: $1.7M contract revenue, $8.4M quarterly net loss, $53.4M cash - TradingView
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics' Oral RT-114 Tops 150% Bioavailability - Stock Titan
Rani Therapeutics at Canaccord Genuity conference: oral biologics push By Investing.com - Investing.com Canada
RANI: Oral biologics platform shows strong clinical and business momentum, with funding secured into 2027 - TradingView
Rani Therapeutics (RANI) Edges Higher by 2.93% as Shares Approach Key $0.84 ResistanceFactor ETF Flow - dars.gov.et
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Rani Therapeutics CEO, CFO to Present, Hold 1x1 Meetings Aug. 12 - Stock Titan
Rani Therapeutics Holdings Inc (RANI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RANI Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Rani Therapeutics appoints Michelle Gilson to board By Investing.com - Investing.com UK
Rani Therapeutics appoints Michelle Gilson to board - The Globe and Mail
Rani Therapeutics Holdings, Inc. (RANI) awards 247,200 stock options to director - Stock Titan
Rani Therapeutics Holdings Inc Azioni (RANI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rani Therapeutics Holdings Inc Azioni (RANI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Javadi Alireza | Chief Technical Officer |
Mar 27 '26 |
Sale |
0.78 |
386 |
301 |
9,689 |
| Imran Talat | Chief Executive Officer |
Jul 17 '26 |
Buy |
0.72 |
35,000 |
25,193 |
469,736 |
| IMRAN MIR A | Director |
Oct 23 '25 |
Buy |
0.60 |
2,083,334 |
1,260,417 |
2,083,334 |
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):